Adaptive Other Operating Expenses from 2010 to 2024
| ADPT Stock | USD 6.46 0.00 0.00% |
Other Operating Expenses | First Reported 2018-03-31 | Previous Quarter 82.6 M | Current Value 79.1 M | Quarterly Volatility 27.2 M |
Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Interest Income of 14.2 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 13.1 M, as well as many indicators such as Price To Sales Ratio of 3.95, Dividend Yield of 0.0 or PTB Ratio of 2.41. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.
Adaptive | Other Operating Expenses |
Latest Adaptive Biotechnologies' Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Adaptive Biotechnologies Corp over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Adaptive Biotechnologies. It is also known as Adaptive Biotechnologies overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Adaptive Biotechnologies' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Adaptive Other Operating Expenses Regression Statistics
| Arithmetic Mean | 173,172,560 | |
| Geometric Mean | 138,775,885 | |
| Coefficient Of Variation | 72.21 | |
| Mean Deviation | 107,490,747 | |
| Median | 82,083,000 | |
| Standard Deviation | 125,053,103 | |
| Sample Variance | 15638.3T | |
| Range | 315.2M | |
| R-Value | 0.84 | |
| Mean Square Error | 4963.6T | |
| R-Squared | 0.71 | |
| Significance | 0.00009 | |
| Slope | 23,483,206 | |
| Total Sum of Squares | 218935.9T |
Adaptive Other Operating Expenses History
About Adaptive Biotechnologies Financial Statements
Adaptive Biotechnologies shareholders use historical fundamental indicators, such as Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 397.3 M | 274.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.